Nipah Virus (NiV) Infection Testing Market

Nipah Virus (NiV) Infection Testing Market Size, Market Forecast and Outlook By FMI

The nipah virus (niv) infection testing market was valued at USD 2.2 billion in 2025. The market is set to reach USD 2.3 billion by 2026-end and grow at a CAGR of 5.2% between 2026-2036 to reach USD 3.8 billion by 2036. RT-PCR Based Kits will dominate with a 63.4% share, while Hospitals will lead with a 52.8% share.

Summary of the Nipah Virus (NiV) Infection Testing Market

• Demand and Growth Drivers
  • Endemic Nipah virus circulation in South and Southeast Asia, combined with epidemic preparedness investment from WHO and national public health agencies, sustains procurement of validated diagnostic testing kits and reagents.
  • Expansion of biosafety level laboratory infrastructure in endemic countries is increasing the capacity for Nipah virus diagnostic confirmation, which was previously limited to a small number of reference laboratories.
  • Development of rapid point of care diagnostic platforms for Nipah virus detection is expected to accelerate outbreak response capability and create new market segments beyond traditional laboratory based molecular testing.
• Product and Segment View
  • RT-PCR Based Kits hold 63.4% of the Test Type segment in 2026, reflecting the established position of real time reverse transcription polymerase chain reaction as the gold standard molecular method for Nipah virus RNA detection in clinical and surveillance specimens.
  • Laboratory-Based Testing accounts for 64.1% of the Testing Mode segment, reflecting the current reliance on biosafety level 3 and reference laboratory infrastructure for Nipah virus diagnostic confirmation.
  • Blood Samples at 46.9% of the Sample Type segment reflects the primary specimen type and diagnostic workflow for Nipah virus clinical testing.
• Geography and Competitive Outlook
  • India leads growth at 6.2% CAGR through 2036, reflecting its position as the most active Nipah virus endemic zone, with recurring outbreaks in Kerala and other southern states driving sustained investment in diagnostic preparedness and surveillance infrastructure.
  • China at 5.8% reflects government investment in emerging infectious disease preparedness, including BSL-3 laboratory expansion and molecular diagnostic stockpiling for priority pathogens including Nipah virus.
  • Diagnostic companies with validated RT-PCR assays, rapid test platforms, and established relationships with public health laboratories in endemic regions are positioned to capture both routine surveillance and outbreak response procurement.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Consultant at FMI says, 'The Nipah virus testing market is driven by epidemic preparedness investment rather than routine diagnostic volume. Companies with validated RT-PCR assays, rapid point of care test platforms, and established distribution relationships with public health laboratories in endemic regions will capture procurement during outbreak response while building installed base for surveillance programs between outbreaks.'
  • The nipah virus (niv) infection testing market is trending toward more formal procurement and supply chain relationships.
  • And as regulations and commercial standards evolve, adoption is increasing.
  • Supportive demand from evolving standards in North America, Europe and East Asia.

Key Takeaways, Market Size, and Forecast

• The nipah virus (niv) infection testing market was valued at USD 2.27 billion in 2025.
• By 2036, the Nipah Virus (NiV) Infection Testing Market is expected to be worth USD 3.81 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 5.2%.
• The market is projected to create an incremental opportunity of USD 1.51 billion between 2026 and 2036.
• In 2026, RT-PCR Based Kits is expected to account for 63.4% of the Test Type, driven by established sensitivity and specificity of RT-PCR molecular detection for Nipah virus RNA in clinical specimens, supported by WHO recommended diagnostic algorithms.
• India (6.2%) and China (5.8%) are two of the fastest growing markets in the world.

Nipah Virus (NiV) Infection Testing Market Definition

The Nipah virus infection testing market encompasses diagnostic products used to detect Nipah virus infection in clinical specimens, including molecular assays (RT-PCR), serological tests (ELISA, immunofluorescence), and rapid diagnostic platforms. Products serve clinical diagnosis, outbreak investigation, surveillance, and research applications.

Nipah Virus (NiV) Infection Testing Market Inclusions

Market scope covers all commercially traded Nipah virus diagnostic products categorized by Test Type, End User, Sample Type, Technology, Testing Mode, Application. Revenue sizing spans the 2026 to 2036 forecast period.

Nipah Virus (NiV) Infection Testing Market Exclusions

The scope does not include general laboratory equipment such as PCR thermocyclers, biosafety cabinets, or centrifuges, Nipah virus vaccine candidates, or therapeutic products for Nipah virus treatment.

Nipah Virus (NiV) Infection Testing Market Research Methodology

• Primary Research: FMI analysts conducted interviews with manufacturers, specialists, and participants across key markets.
• Desk Research: Combined industry databases, regulatory filings, publications, and manufacturer disclosures.
• Market Sizing and Forecasting: Bottom up aggregation across segments, applications, and regions with adoption curve modeling.
• Data Validation: Cross checked quarterly against statistics, trade data, and reported figures.

Why is the Nipah Virus (NiV) Infection Testing Market Growing?

• The WHO designation of Nipah virus as a priority pathogen for epidemic preparedness research and development continues to support international funding for diagnostic development, stockpiling and laboratory capacity building in endemic regions.
• Routine surveillance testing needs of public health labs are well known, but acute diagnostic procurement surges can occur when Nipah virus outbreaks recur in India and Bangladesh.
• India leads growth at a 6.2% CAGR, reflecting a recurring experience of outbreaks, increasing BSL-3 laboratory capacity, and government investment in molecular diagnostic preparedness for priority pathogens.

The Nipah Virus Infection Testing Market is witnessing growth as the investment in epidemic preparedness and recurrent outbreaks fuel diagnostic procurement. The test type segment is dominated by RT-PCR based kits with 63.4% of the segment share, suggesting the proven sensitivity and specificity of the molecular detection methods for Nipah virus RNA in clinical samples such as serum, cerebrospinal fluid and respiratory secretions. Serological assays including ELISA based IgM and IgG detection are complementary in outbreak investigation and seroprevalence studies.

Demand patterns in the market are episodic in nature and driven by outbreak events with a baseline of surveillance and preparedness procurement superimposed. When an outbreak occurs, the demand for diagnostic kits increases as public health laboratories, hospitals in the outbreak area and international outbreak response agencies begin testing. Demand during the inter-epidemic period is met through national laboratory stockpiling programmes, surveillance testing in endemic areas and use by research laboratories.

The most important near term market expansion opportunity is rapid point of care diagnostic development. Existing testing for Nipah virus requires biosafety level 3 laboratory infrastructure and trained molecular biology personnel, limiting testing capacity during outbreaks. The availability of rapid diagnostic tests that could be performed at lower biosafety levels or in the field would greatly increase the testing capacity and accelerate the control of the outbreak. New market segments would develop beyond the traditional procurement by reference laboratories.

Market Segmentation Analysis

• RT-PCR Based Kits Hold 63.4% of Test Type Segment
• 64.1% of the Testing Mode segment comes from Laboratory-Based Testing.
• Blood Samples at 46.9% of the Sample Type segment expresses Functional preferences.

The Nipah Virus (NIV) Infection Testing Market is segmented on the basis of Test Type, End User, Sample Type, Technology, Testing Mode, Application.

Insights into the RT-PCR Based Kits Test Type Segment

RT-PCR Based Kits is expected to register a share of 63.4% of the Test Type segment in 2026. This is testimony to steady demand with rt-pcr based kits showing reliable performance. Sub segments are distinguished by specification and price. Reliability, compliance and quality are the basis for procurement decisions.

Insights into the Laboratory-Based Testing Testing Mode Segment

Laboratory-Based Testing segment has 64.1% share of the Testing Mode segment. Markets are growing and standardization is driving growth Buyers consider performance, cost issues and availability of support.

Nipah Virus (NiV) Infection Testing Market Drivers, Restraints, and Opportunities

• Regulatory frameworks create structured demand for compliant products.
• Cost constraints and supply limitations present margin risks.
• Application expansion creates incremental growth opportunities.

The nipah virus (niv) infection testing market is shaped by regulatory mandates, shifting requirements, and competitive dynamics.

Epidemic Preparedness Investment and WHO Priority Pathogen Status

Demand is shaped by international and national investment in epidemic preparedness for WHO priority pathogens. Nipah virus is classified alongside Ebola, MERS, and other high consequence pathogens that receive dedicated research and development funding, diagnostic stockpiling, and laboratory capacity building investment. This preparedness framework sustains baseline procurement between outbreaks.

Limited Endemic Range and Episodic Demand Patterns

Growth is constrained by the geographically limited endemic range of Nipah virus, concentrated primarily in South and Southeast Asia. The episodic nature of outbreaks creates demand volatility that makes sustained commercial investment challenging for diagnostic manufacturers. Companies must balance the cost of maintaining validated assays and manufacturing readiness against the unpredictable timing and scale of outbreak driven procurement.

BSL-3 Laboratory Capacity Expansion in Endemic Countries

Adoption is increasing due to government investment in biosafety level 3 laboratory infrastructure in Nipah virus endemic countries, particularly India and Bangladesh. Expanded BSL-3 capacity enables more facilities to perform confirmatory Nipah virus testing, reducing dependence on single reference laboratories and increasing the total testing volume that the diagnostic market can serve.

Rapid Point of Care Diagnostic Development

Growth reflects advancing development of rapid diagnostic platforms that can detect Nipah virus outside traditional BSL-3 laboratory settings. Lateral flow assays, isothermal amplification platforms, and portable molecular testing devices designed for field deployment represent emerging product categories that could expand the testing market by enabling point of care diagnosis during outbreak response.

Analysis of Nipah Virus (NiV) Infection Testing Market By Key Countries

Country	CAGR
USA	5.5%
UK	5.0%
France	4.8%
Germany	5.3%
Italy	4.7%
South Korea	5.6%
Japan	4.9%
China	5.8%
Australia - New Zealand	5.4%
India	6.2%

• India leads with 6.2% CAGR through 2036.
• China at 5.8% demonstrates sustained demand.
• USA (5.5%) reflects steady demand.

The global nipah virus (niv) infection testing market is projected to grow at 5.2% CAGR from 2026 to 2036, covering more than 30 countries.

Demand Outlook for Nipah Virus Testing Market in the United States

The United States is expected to grow at 5.5% CAGR through 2036. US demand is driven by CDC and BARDA pandemic preparedness stockpiling for priority pathogens including Nipah virus, with BSL-4 laboratory infrastructure at institutions like USAMRIID and CDC providing reference diagnostic capability and driving procurement of validated molecular detection kits for surge readiness.

• CDC and BARDA preparedness programs sustain diagnostic kit stockpiling.
• BSL-4 laboratory reference capability drives validated assay procurement.
• Biodefense research programs generate laboratory diagnostic reagent demand.

Future Outlook for Nipah Virus Testing Market in India

India is expected to grow at 6.2% CAGR through 2036. India is the most active Nipah virus endemic zone, with recurring outbreaks in Kerala driving sustained investment in BSL-3 diagnostic laboratory capacity, state level molecular testing capability, and stockpiling of RT-PCR kits at the National Institute of Virology and regional surveillance laboratories.

• Recurring Kerala outbreaks sustain diagnostic preparedness investment.
• BSL-3 laboratory capacity expansion enables decentralized confirmatory testing.
• State and district level stockpiling programs maintain molecular testing readiness.

Opportunity Analysis of Nipah Virus Testing Market in China

China is expected to grow at 5.8% CAGR through 2036. Government emerging infectious disease preparedness programs, including the Chinese CDC Priority Pathogen Surveillance Network, sustain procurement of molecular diagnostic assays for Nipah virus and other WHO priority pathogens across the national BSL-3 and BSL-4 laboratory network.

• Priority Pathogen Surveillance Network sustains molecular diagnostic procurement.
• BSL-3 and BSL-4 laboratory infrastructure investment expands testing capacity.
• Domestic diagnostic manufacturer development creates localized kit supply sources.

In-depth Analysis of Nipah Virus Testing Market in Germany

Germany is expected to grow at 5.3% CAGR through 2036. The Bernhard Nocht Institute for Tropical Medicine and Robert Koch Institute maintain reference diagnostic capability for Nipah virus, with German participation in EU Joint Procurement of medical countermeasures sustaining diagnostic stockpiling for high consequence pathogens.

• Reference laboratory capability at BNI and RKI anchors national diagnostic readiness.
• EU Joint Procurement sustains diagnostic stockpiling for priority pathogens.
• Tropical medicine research programs generate ongoing laboratory diagnostic demand.

Sales Analysis of Nipah Virus Testing Market in South Korea

South Korea is expected to grow at 5.6% CAGR through 2036. South Korea's experience with MERS outbreak response has reinforced investment in diagnostic preparedness for emerging infectious diseases, with KCDC maintaining stockpiles of validated molecular assays for WHO priority pathogens including Nipah virus and supporting rapid deployment testing capability.

• MERS experience reinforced investment in emerging pathogen diagnostic preparedness.
• KCDC maintains validated molecular assay stockpiles for priority pathogens.
• Rapid deployment diagnostic capability supports regional outbreak response capacity.

In-depth Analysis of Nipah Virus Testing Market in Australia and New Zealand

Australia and New Zealand is expected to grow at 5.4% CAGR through 2036. Geographic proximity to Nipah endemic regions in Southeast Asia drives Australian investment in BSL-4 diagnostic capability at the Australian Centre for Disease Preparedness (ACDP) in Geelong, with national stockpiling programs maintaining molecular testing capacity for imported case detection.

• ACDP BSL-4 laboratory provides national reference diagnostic capability.
• Geographic proximity to endemic regions drives preparedness investment.
• National stockpiling programs maintain testing readiness for imported case scenarios.

Competitive Landscape and Strategic Positioning

• Thermo Fisher Scientific maintains the strongest position through capability and portfolio breadth.
• Roche Diagnostics, Abbott Laboratories, QIAGEN compete through specialization and expertise.
• Emerging players focus on niche applications and differentiation.

Thermo Fisher Scientific holds the strongest competitive position through technical capability, established relationships, and portfolio breadth across primary segments.

Roche Diagnostics, Abbott Laboratories, QIAGEN compete through specialized capabilities, application expertise, and targeted strategies in specific segments or geographies.

Barriers to entry include technical expertise, regulatory compliance, established relationships, and capital requirements. New participants focus on niche opportunities.

Strategic priorities include cost optimization, geographic expansion, portfolio extension, and investment in capabilities that strengthen customer retention.

Key Companies in the Nipah Virus (NiV) Infection Testing Market

Key global companies leading the nipah virus (niv) infection testing market include:

• Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, QIAGEN maintain strong positions through integrated capabilities.
• Bio-Rad Laboratories, Siemens Healthineers, Cepheid compete through regional specialization.
• Lunit, Owlstone Medical, Biovac, CDC (USA), NIV-Pune (India), CEPI (Coalition for Epidemic Preparedness Innovations), WHO are establishing presence through niche focus.

Competitive Benchmarking: Nipah Virus (NiV) Infection Testing Market

Company	Assay Portfolio	Regulatory Status	Distribution Network	Manufacturing Readiness
Thermo Fisher Scientific	High	High	Strong	Global
Roche Diagnostics	High	High	Strong	Global
Abbott Laboratories	High	High	Strong	Global
QIAGEN	Medium	High	Moderate	Global
Bio-Rad Laboratories	Medium	Medium	Moderate	Regional
Siemens Healthineers	Medium	Medium	Moderate	Regional
Cepheid	Low	Medium	Low	Regional
Lunit	Low	Medium	Low	Niche
Owlstone Medical	Low	Medium	Low	Niche
Biovac	Low	Medium	Low	Niche

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Nipah Virus (NiV) Infection Testing Market

• In 2025, Thermo Fisher Scientific continued to supply advanced RT‑PCR platforms and molecular diagnostic reagents used for highly pathogenic virus testing, including Nipah virus, in key markets such as India.
• In 2025, Roche Diagnostics maintained its position as a key provider of high‑throughput molecular diagnostic systems used for highly pathogenic viral testing and outbreak surveillance in reference laboratories, including NiV‑affected regions such as India.

Key Players in the Nipah Virus (NiV) Infection Testing Market

Major Global Players

• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• QIAGEN
• Bio-Rad Laboratories
• Siemens Healthineers
• Cepheid

Emerging Players/Startups

• Lunit
• Owlstone Medical
• Biovac
• CDC (USA)
• NIV-Pune (India)
• CEPI (Coalition for Epidemic Preparedness Innovations)
• WHO

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 2.29 billion to USD 3.81 billion, at a CAGR of 5.2%
Market Definition	The nipah virus (niv) infection testing market encompasses commercially traded products categorized by Test Type, End User, Sample Type, Technology, Testing Mode, Application.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, Australia - New Zealand, India, 30 plus countries
Key Companies Profiled	Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Siemens Healthineers, Cepheid, Lunit, Owlstone Medical, Biovac, CDC (USA), NIV-Pune (India), CEPI (Coalition for Epidemic Preparedness Innovations), WHO
Forecast Period	2026 to 2036
Approach	Hybrid bottom up and top down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Segmentation

Nipah Virus (NiV) Infection Testing Market Segmented by Test Type:

• RT-PCR Based Kits
  • Real-Time RT-PCR Assays
  • Multiplex PCR Detection Kits
• ELISA Kits
  • IgM Antibody Detection Kits
  • IgG Serological Test Kits

Nipah Virus (NiV) Infection Testing Market Segmented by End User:

• Hospitals
  • Infectious Disease Departments
  • Emergency Diagnostic Units
• Diagnostic Centres
  • Private Diagnostic Labs
  • Public Health Testing Facilities
• Research Labs
  • Virology Research Institutes
  • Academic Research Centers

Nipah Virus (NiV) Infection Testing Market Segmented by Sample Type:

• Blood Samples
  • Serum Samples
  • Plasma Samples
• Respiratory Samples
  • Throat Swabs
  • Nasal Swabs
• Urine & Other Fluids
  • Urine Samples
  • Cerebrospinal Fluid (CSF)

Nipah Virus (NiV) Infection Testing Market Segmented by Technology:

• Molecular Diagnostics
  • PCR-Based Testing
  • Nucleic Acid Amplification
• Immunoassays
  • ELISA-Based Detection
  • Antigen-Antibody Testing
• Rapid Diagnostic Tests
  • Point-of-Care Testing Kits
  • Lateral Flow Assays

Nipah Virus (NiV) Infection Testing Market Segmented by Testing Mode:

• Laboratory-Based Testing
  • Centralized Diagnostic Laboratories
  • High-Throughput Testing Facilities
• Point-of-Care Testing
  • Rapid Field Testing Kits
  • Portable Diagnostic Devices

Nipah Virus (NiV) Infection Testing Market Segmented by Application:

• Clinical Diagnosis
  • Symptomatic Patient Testing
  • Hospital-Based Screening
• Surveillance & Monitoring
  • Outbreak Tracking Programs
  • Public Health Screening Initiatives
• Research Applications
  • Virology Studies
  • Vaccine Development Research

Nipah Virus (NiV) Infection Testing Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO R&D Blueprint: Priority Pathogens for Epidemic Preparedness. WHO.
• 2. National Institute of Virology India. (2025). NIV Nipah Virus Diagnostic Protocol and Surveillance Guidelines. NIV.
• 3. Centers for Disease Control and Prevention. (2025). CDC Nipah Virus Information: Diagnostic and Laboratory Resources. CDC.
• 4. Coalition for Epidemic Preparedness Innovations. (2025). CEPI Nipah Virus Countermeasure Portfolio. CEPI.
• 5. Food and Agriculture Organization. (2025). FAO One Health Approach: Nipah Virus Spillover Surveillance. FAO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Addresses

• Estimating market size and revenue from 2026 to 2036.
• Segmentation by product, application, end use, and region.
• Insights about more than 30 regional markets.
• Technology, manufacturing, and supply chain analysis.
• Competitive landscape assessment.
• Investment opportunity identification.
• Supply chain and distribution analysis.
• Data delivery in PDF and Excel formats.